Both the EGFR and IGFR pathways can stimulate metabolic cell modifications in a coordinated way, acting as neoplasm promoters forming a feedback system; evidence portrays that metformin treatment may oppose some of these changes and thus exert antitumor activity (Figure 2). This evidence concerns the gene EGFR and neoplasm.